Insomnia is common among people with drug-resistant depression and can undermine treatment and quality of life. In a comparison of 50 patients, those taking esketamine combined with other antidepressants had less insomnia than those taking other antidepressants alone. Longer use and higher doses of esketamine were associated with further reductions in insomnia. Esketamine produces a rapid improvement in sleep quality, offering an advantage over standard antidepressants for this population.
About 3.9% of people worldwide experience Post Traumatic Stress Disorder (PTSD) in their lifetime, a condition marked by intrusive thoughts, hyperarousal, and avoidance after trauma. Standard treatments like psychotherapy and medication help only modestly for many, leaving chronic symptoms and related health problems. This narrative review synthesizes current knowledge on novel treatments, focusing on psychedelic drugs. It examines research on psychedelic therapy for PTSD, weighing benefits and drawbacks of different interventions, and asks what psychedelic-based pharmacological treatments exist or are emerging for PTSD patients and how they might be integrated into future clinical care. The review aims to offer practitioners and patients insights into the potential role of psychedelic compounds in PTSD treatment.